| ￥3300 | |
| Z04895-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized PDGF R beta/CD140b, His, Cynomolgus at 2μg/ml (100μl/well) on the plate can bind AntiPDGFRB Antibody, hFc Tag. Test result was comparable to standard batch | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 57.49 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 75-105 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Platelet-derived growth factor receptor (PDGFR) signaling is involved in proliferation and survival in a wide array of cell types.PDGFR-β signalling, via TGF-β signalling, may be crucial for restoration of BBB integrity after cerebral ischemia and therefore represents a novel potential therapeutic target. |
| Synonyms | PDGF-R-beta; PDGFR-beta; PDGFRB; PDGF R beta; PDGFR-2; PDGFR-β |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
